Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas

Virchows Archiv

Volumn 430, Issue 1, 1997, Pages 17-22

  Kapucuoglu, Nilgun ^a   Losi, Luisa ^b   Eusebi, Vincenzo ^b,c  

^a SB Onkoloji Hastanesi ^*  (Turkey)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c BELLARIA HOSPITAL   (Italy)

Author keywords

Bax; Bcl 2; Breast carcinoma; Grading

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER GRADING; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTO ONCOGENE;

BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; HUMANS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0031016276     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01008011     Document Type: Article

References (34)

1. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dorken B (1995) Expression of the bcl-2 gene family in normal and malignant breast tissue:low bax-alfa expression in tumour cells correlates with resistance towards apoptosis. Int J Cancer 60:854-859
2. Barinaga M (1994) Cell suicide: by ICE, not fire. Science 263:754-756
3. Bhargava V, Kell DL, Van de Rijn M, Warlike RA (1994) Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540
4. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR (1994) The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 11:199-207
5. Cerroni L, Soyer HP, Kerl H (1995) Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 17:7-11
6. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400
7. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G (1994) The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to estrogen receptor status. Virchows Arch 424:47-51
8. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer experience from a large study with long-term follow-up. Histopathology 19:403-410
9. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, Di Palma S, Rilke F (1994) Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 11:223-235
10. Gee JMW, Robertson JFR, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI (1994) Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59:619-628
11. Hockenbery DM, Zutter M, Mickey W, Nahm M, Korsmeyer SJ (1991) Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965
12. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, Van de Vijver MJ, Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11:167-180
13. Hurlimann J, Larrinaga B, Vala DLM (1995) Bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 426:163-168
14. Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191-1198
15. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC (1994) Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145:1323-1336
16. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC (1995) Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic adenocarcinoma. Cancer Res 55:4471-4478
17. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) Bcl-2 in normal human breast and carcinoma , association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 6:135-139
18. Lu QL, Abel P, Foster CS, Lalani EN (1996) Bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 27: 102-110
19. Manetto V, Lorenzini R, Cordon-Cardo C, Krajewski S, Rosai J, Reed JC, Eusebi V. (1996) Relationship of Bcl-2 and Bax expression with differentiation in thyroid tumors: an immunohistochemical and western blot analysis. Virchows Arch (in press)
20. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
21. Nathan B, Anbazhagan R, Clarkson P, Bartkova J, Gusterson B (1994) Expression of Bcl-2 in the developing human fetal and infant breast. Histopathology 24:73-76
22. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML (1988) Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 318:1638-1644
23. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619
24. Pezzella F, Gatter K (1995) What is the value of bcl-2 protein detection for histopathologists? Histopathology 26:89-93
25. Pezzella H, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY (1990) Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 137:225-232
26. Pezzella F, Morrison H, Jones M, Gatter KC, Lane D, Harris AL, Mason DY (1993) Immunohistochemical detection of p53 and bcl-2 in non-Hodgkin's lymphoma. Histopathology 22: 39-44
27. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY (1993) Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694
28. Sabourin JC, Martin A, Baruch J, Truc JB, Gompel A, Poitout P (1994) Bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 59:1-6
29. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504
30. Siriaunkgul S, Tavassoli FA (1993) Invasive micropapillary carcinoma of the breast. Mod Pathol 6:660-662
31. Siziopikou KP, Prioleau J, Schnitt S (1996) MIB-1 proliferation index (PI) in ductal carcinoma in situ (DCIS): relationship to bcl-2 and p53 protein. Lab Invest 126:25A
32. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC (1995) Cloning and functional analysis of Bag-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 80:279-284
33. Vaux DL (1993) Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 90:786-789
34. Yang E, Zha J, Jockei J, Boise LH, Thompson CB, Korsmeyer SJ (1995) Bad, a heterodimeric partner for Bcl-xL and Bel-2, displaces Bax and promotes cell death. Cell 80:285-291